SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hawkins, D.F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hawkins, D.F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Assessment of teratogenicity

D.F. Hawkins

Emeritus Professor of Obstetric Therapeutics, University of London, Hammersmith Hospital, London W12 OHS, UK

Animal tests for teratogenicity of drugs have more medicolegal and political significance than relevance to human therapeutics. Test conditions differ widely from human therapeutic regimens and major species differences are common. Occasionally the tests will define a drug or group of drugs with an unpleasant potential, and sometimes a mode of action which needs careful exploration in humans will be found. Anecdotal case reports of purported associations between drug use and congenital malformations provide a vast source of misinformation, yet they were responsible for the indictment of thalidomide as a human teratogen. Retrospective studies on patients who have taken a drug in pregnancy are susceptible to recall bias, and at best provide a basis for planned prospective studies which are seldom instituted for fear of medicolegal consequences. Prospective surveillance of drugs already accepted for use in pregnancy and reporting of `adverse reactions' to drugs inadvertently used in pregnancy thus provide the only effective source of information on teratogenicity of psychotropic drugs in humans.

Key Words: psychotropic drugs • pregnancy • teratogenicity

Journal of Psychopharmacology, Vol. 6, No. 2, 225-229 (1992)
DOI: 10.1177/026988119200600216


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
J.G. Edwards
Methods of assessing unwanted effects of psychotropic drugs. General considerations and overview
J Psychopharmacol, January 1, 1992; 6(2): 191 - 197.
[PDF]



Advertisement